Suppliers and packagers for ORAVIG

Oravig (miconazole) suppliers: who makes, licenses, and distributes the dental buccal tablet?

Oravig (miconazole buccal tablet) is supplied through a branded-commercial network that includes the original NDA holder and multiple distribution and manufacturing supply roles. The key supplier categories that matter for contracting and competitive diligence are: (1) NDA holder/brand marketer, (2) contract manufacturer(s) for the drug product, (3) active pharmaceutical ingredient (API) suppliers for miconazole, and (4) distribution/wholesale and wholesaler-to-pharmacy channels.

Because “suppliers” can mean different things, the commercial diligence answer is structured by supplier role: brand holder, drug-product manufacturing, API supply, and channel/distribution.

Who is the NDA holder and main brand supplier for Oravig (miconazole) tablets?

Primary brand-supply role: the entity holding the US New Drug Application and marketing Oravig is the top “supplier” for commercial supply chain mapping and pricing/licensing workflows (wholesale orders, chargebacks, and tenders originate with the brand owner’s distribution program).

Named brand entity and market-facing supplier: Sandoz Inc. is the current US commercial brand owner/labeler for Oravig in the US market, with commercial distribution executed via its distribution partners and standard pharmaceutical wholesaler channels.

Regulatory listing anchor (Orange Book labeler): The Orange Book labeler for Oravig is the controlling reference point for contract and licensing linkage.

Who manufactures Oravig (miconazole) drug product under contract?

For buccal tablets, supplier diligence typically turns on contract manufacturing relationships (CMOs) that produce:

• the final oral-dental buccal tablet (drug product),
• packaging (blistering/dispensing packs),
• and stability/labeling batch records used for commercial release.

Key point for supplier mapping: Oravig’s drug-product manufacturing is generally handled by one or more contract manufacturers under Sandoz’s labeler program. For legal and procurement use, the controlling evidence is the CGMP facility listed by batch labeling/distribution records and any facility disclosures tied to NDA manufacturing sections and later supplements.

Which companies supply miconazole API used in Oravig?

Oravig’s active ingredient is miconazole (antifungal imidazole). API supply is normally tiered:

• upstream API synthesis,
• API crystallization and milling,
• and downstream drug-product formulation/compaction.

Procurement-relevant supplier categories:

• miconazole API manufacturers for US commercial supply
• API repackagers and intermediaries (rarely the true synthesis source)
• suppliers that qualify for regulatory and quality agreements (DMF/CEP-linked suppliers)

Key diligence anchor: identify miconazole API suppliers linked to the NDA through DMF cross-references and/or quality documentation referenced in regulatory filings, then map which of those suppliers actually supply Sandoz’s batch release supply chain.

How does the distribution network for Oravig work: wholesalers, pharmacy channels, and direct accounts?

Oravig is distributed through standard pharmaceutical channel partners:

• national wholesalers,
• regional wholesalers,
• group purchasing organization (GPO) supply networks,
• and specialty pharmacy relationships where applicable.

Commercial “supplier” reality: For most buyers, the immediately actionable suppliers are the wholesalers that hold Oravig inventory and provide consistent delivery windows. Brand owners typically do not sell direct to many retail pharmacies at scale; they flow product through wholesaler systems.

What Orange Book status does Oravig have and what does that imply for supplier/manufacturer switching?

Orange Book status controls exclusivity and patent barriers, but it also indirectly constrains manufacturing switching because any generic or pathway substitution typically requires:

• ANDA (for small molecules) with bioequivalence,
• patent certifications (Paragraph IV or other),
• and manufacturing controls that satisfy FDA chemistry, manufacturing, controls, and labeling requirements.

For supplier mapping, Orange Book helps determine:

• whether manufacturing is stable under the NDA (brand supply continuity),
• whether entrants exist that could pressure supplier pricing or capacity.

Are there generic Oravig equivalents or authorized generics that affect supplier landscape?

If an ANDA has launched or an authorized generic exists, it can change “who the suppliers are” in two ways:

1. upstream API and CMO contracting shifts toward the entrant’s manufacturing plan,
2. brand market share declines, which can change the brand owner’s manufacturing utilization and CMO relationships.

A current market-supplier picture requires checking for:

• approved generic NDA entries,
• FDA approvals for therapeutically equivalent buccal miconazole products,
• and any exclusivity-linked delay.

Which formulation and process suppliers matter for Oravig buccal tablet quality?

For buccal tablets, suppliers that impact product performance include:

• tablet formulation development teams (adhesion mechanics, mucoadhesion performance),
• granulation and compression process owners,
• blister packaging equipment and line-validation providers,
• and quality testing labs that support dissolution and content uniformity release.

Procurement-limiting items typically include:

• validated mucoadhesive excipient sourcing,
• consistent dissolution and in vitro release profiles,
• stability program ownership and ongoing change control.

How many manufacturing sites supply Oravig, and where are they located?

For supplier selection, buyers typically need:

• number of commercial manufacturing sites,
• geography and logistics constraints,
• regulatory inspection history,
• and change-control track record.

This is usually sourced from:

• NDA manufacturing section disclosures,
• facility listings associated with annual product reports,
• and any FDA inspection outcomes associated with the sites used for commercial lots.

What patent or exclusivity factors affect Oravig supply continuity and CMO contracting?

Even when suppliers change at the contract-manufacturer level, the brand’s regulatory pathway stability matters:

• If no generic entrants are active, brand production runs remain uninterrupted.
• If patent cliffs exist or Paragraph IV litigation is ongoing, brand supply strategy can shift to preserve shelf supply and support legal timelines.

This supplier effect is more pronounced for scarce APIs or specialized buccal-tablet process capabilities.

Key Takeaways

• Oravig’s top “supplier” for commercial transactions is the US labeler/brand owner: Sandoz Inc.
• The practical supplier set for procurement includes (1) brand distribution wholesalers, (2) contract manufacturers producing the buccal tablet, and (3) upstream miconazole API suppliers tied to NDA quality documentation.
• The supplier landscape can change materially if generic buccal miconazole equivalents are approved and launch, altering CMO utilization and API contracting.

FAQs

1) Who supplies Oravig to pharmacies in the US?
Oravig is supplied via national and regional pharmaceutical wholesalers operating through standard retail distribution channels under the brand owner’s distribution program.

2) What is the active ingredient in Oravig and what does that mean for API sourcing?
Oravig’s active ingredient is miconazole; API sourcing depends on qualified miconazole suppliers linked to the NDA’s quality documentation (often via DMF references).

3) Can Oravig contract manufacturers change without affecting product approval?
They can change with approved supplements and validated manufacturing transfer controls, as long as the FDA-approved quality and process requirements are met.

4) Do Orange Book listings determine who can supply Oravig generics?
They determine the legal and regulatory entry path (bioequivalence and patent certifications) that governs whether generic competitors can supply therapeutically equivalent products.

5) Does the buccal tablet form create special supplier constraints?
Yes. Buccal tablet quality depends on formulation, mucoadhesive performance, and validated packaging and release testing, which narrows the pool of qualified manufacturers.

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm